McKesson Restructures Business Segments to Focus on High-Growth Healthcare Areas
McKesson Corporation is reorganizing its reporting structure to enhance strategic alignment and transparency, focusing on accelerating growth in oncology, multispecialty, and biopharma services while optimizing portfolio management for long-term shareholder value.
McKesson Corporation has announced significant changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting framework aims to enhance strategic alignment and transparency while supporting optimized portfolio management to drive sustainable long-term value creation for shareholders.
Britt Vitalone, chief financial officer, stated that this updated reporting structure reflects a strategic evolution of the business, accelerating growth in high-margin areas including oncology, multispecialty, and biopharma services. The changes reinforce the company's disciplined approach to capital allocation and shareholder value creation while maintaining McKesson's long history of leadership in healthcare.
The new reportable segments include North American Pharmaceutical, which combines McKesson's scaled wholesale drug distribution businesses in the United States and Canada. This segment delivers distribution services to retail and community pharmacies, along with institutional healthcare providers.
Oncology and Multispecialty represents a newly defined segment that includes integrated solutions across oncology and multispecialty providers. This encompasses specialty provider solutions, practice management services supporting physician-led oncology networks, and services for other multispecialty providers including retina and ophthalmology. The segment also offers clinical trial services, specialty pharmacy solutions, and technology-driven innovation.
Prescription Technology Solutions connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma through differentiated networks, improving medication access and affordability while delivering measurable value to biopharma partners.
Medical-Surgical Solutions delivers medical-surgical supply distribution, logistics, and related services to healthcare providers across alternate sites of care. McKesson announced in May 2025 its intention to separate this segment into an independent company, signaling a strategic shift in its portfolio management approach.
The Other segment includes distribution and retail operations in Norway, though McKesson entered into a definitive agreement on August 4, 2025, to sell these businesses, subject to customary closing conditions and regulatory approvals. Additional details regarding the new reporting structure will be shared during the company's Investor Day on September 23, 2025, where leadership will provide further insights into the strategic rationale behind these organizational changes.